Published in J Clin Oncol on September 01, 1988
Risk and prognostic factors in trophoblastic neoplasia. Cancer (1976) 3.12
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Radioimmunoassay for human chorionic gonadotrophin and luteinising hormone. Lancet (1966) 2.82
Tumour growth and anti-mitotic action. The role of spontaneous cell losses. Br J Cancer (1968) 2.34
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer (1993) 2.18
Choriocarcinoma and partial hydatidiform moles. Lancet (2000) 2.15
Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer (2000) 2.07
Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol (2002) 2.06
Hydatidiform mole in England and Wales 1973-83. Lancet (1986) 2.05
Phase I trial of elactocin. Br J Cancer (1996) 2.01
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol (1997) 2.00
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet (1991) 1.95
Further advances in the management of malignant teratomas of the testis and other sites. Lancet (1983) 1.80
Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet (1987) 1.79
Accurate quantification of 131I distribution by gamma camera imaging. Eur J Nucl Med (1990) 1.78
Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res (1998) 1.70
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol (1997) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer (2000) 1.66
A review of the role of established tumour markers. Ann Clin Biochem (1991) 1.65
The masking of antigens on trophoblast and cancer cells. Lancet (1967) 1.65
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer (1993) 1.60
Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer (1969) 1.59
Effects of microwave cookery on the bacterial counts of food. J Appl Bacteriol (1965) 1.58
ABO blood-groups in trophoblastic neoplasia. Lancet (1971) 1.56
Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer (1990) 1.56
Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol (1996) 1.54
Carboplatin or cisplatin? Lancet (1988) 1.53
Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol (1986) 1.53
Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer (1980) 1.49
Phase I clinical trial of mitozolomide. Cancer Treat Rep (1985) 1.48
Chemotherapy for ovarian germ cell tumours. Eur J Cancer (1996) 1.48
Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol (1986) 1.48
A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin. J Immunol Methods (1976) 1.47
Rapid diagnosis and classification of hydatidiform moles with polymerase chain reaction. Am J Obstet Gynecol (1993) 1.45
Effect of neuraminidase on the immunogenicity of early mouse trophoblast. Nature (1968) 1.44
In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br J Cancer (1999) 1.42
The role of sialic acid in antigenic expression: further studies of the Landschütz ascites tumour. Br J Cancer (1968) 1.42
POMB/ACE chemotherapy for mediastinal germ cell tumours. Eur J Cancer (1997) 1.40
Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics. Lancet (1999) 1.40
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer (1983) 1.40
Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. Br J Cancer (1990) 1.39
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer (1996) 1.38
Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours. Ann Oncol (1992) 1.38
The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care (1997) 1.37
Distribution of the Ca (Oxford) antigen in lung neoplasms and non-neoplastic lung tissues. J Clin Pathol (1984) 1.35
The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol (1989) 1.35
Choriocarcinoma after hydatidiform mole. Studies related to effectiveness of follow-up practice after hydatidiform mole. Br Med J (1969) 1.34
Follow-up after hydatidiform mole: studies using radioimmunoassay for urinary human chorionic gonadotrophin (HCG). J Obstet Gynaecol Br Commonw (1973) 1.34
Characterization of immune complexes in serum by adsorption on staphylococcal protein A: model studies and application to sera of rats bearing a gross virus-induced lymphoma. J Immunol (1978) 1.33
Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG (2003) 1.32
Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer (1979) 1.32
In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs (1997) 1.32
Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase. Nature (1968) 1.31
Presentation and management of choriocarcinoma after nonmolar pregnancy. Br J Obstet Gynaecol (1995) 1.31
Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer (1983) 1.31
Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer (1976) 1.30
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
Radioimmunoassay methods for carcinoembryonic antigen. J Immunol Methods (1974) 1.27